A Phase 1, Dose Expansion Of A Within-Cohort, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Single-And Multiple-Dose Escalation Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults
Latest Information Update: 12 Nov 2014
At a glance
- Drugs PF 6473871 (Primary)
- Indications Scars
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 09 May 2014 New trial record